Neuroblastoma is an embryonic tumour of the sympathetic nervous system and is one of the most common cancers in childhood. A high differentiation stage has been associated with a favourable outcome; however, the mechanisms governing neuroblastoma cell differentiation are not completely understood. The MYCN gene is considered the hallmark of neuroblastoma. Even though it has been reported that MYCN has a role during embryonic development, it is needed its decrease so that differentiation can be completed. We aimed to better define the role of MYCN in the differentiation processes, particularly during the early stages. Considering the ability of MYCN to regulate non-coding RNAs, our hypothesis was that N-Myc protein might be necessary to activate differentiation (mimicking embryonic development events) by regulating miRNAs critical for this process. We show that MYCN expression increased in embryonic cortical neural precursor cells at an early stage after differentiation induction. To investigate our hypothesis, we used human neuroblastoma cell lines. In LAN-5 neuroblastoma cells, MYCN was upregulated after 2 days of differentiation induction before its expected downregulation. Positive modulation of various differentiation markers was associated with the increased MYCN expression. Similarly, MYCN silencing inhibited such differentiation, leading to negative modulation of various differentiation markers. Furthermore, MYCN gene overexpression in the poorly differentiating neuroblastoma cell line SK-N-AS restored the ability of such cells to differentiate. We identified three key miRNAs, which could regulate the onset of differentiation programme in the neuroblastoma cells in which we modulated MYCN. Interestingly, these effects were accompanied by changes in the apoptotic compartment evaluated both as expression of apoptosis-related genes and as fraction of apoptotic cells. Therefore, our idea is that MYCN is necessary during the activation of neuroblastoma differentiation to induce apoptosis in cells that are not committed to differentiate.
Subject Category: Cancer
Neuroblastoma is an embryonic tumour of the sympathetic nervous system and is one of the most common childhood cancers. The clinical signs and symptoms of neuroblastoma are extremely variable. 1 A high differentiation stage has been associated with a favourable outcome; 1 however, the mechanisms governing neuroblastoma cell differentiation are not completely understood. Nevertheless, the ability of many neuroblastoma cell lines to maintain their differentiation capability in vitro has made them suitable models for studying human neuronal differentiation. 2 It is well known that the MYC family member N-Myc, encoded by MYCN, has a key role during neuroblastoma differentiation. N-Myc has been found to be overexpressed in approximately 25% of primary neuroblastoma tumours. 3 The MYC gene family is composed of three members, MYC, MYCN and MYCL. The Myc proteins act as transcription factors: they recognise a consensus sequence (CACGTG) known as the E-box sequence and form a heterodimeric complex with their functional partner, Max. The Myc-Max heterodimer recruits other transcriptional co-factors and activates or represses gene expression. 4, 5 Similar to the other Myc proteins, N-Myc is a transcription factor that controls the expression of many target genes involved in fundamental cellular processes. 6, 7 c-Myc was found to be overexpressed in Burkitt lymphomas; however, during mouse embryogenesis and in highly proliferative adult tissues it is usually expressed, functioning as an inhibitor of differentiation processes and a promoter of cell proliferation. 8 Interestingly, MYCN shows a more targeted expression pattern, with temporal and tissue specificity. It is first detected during the seventh day of pregnancy, is observed at high levels during the ninth and eleventh days and rapidly decreases after the twelfth day. 9, 10 The importance of MYCN expression during the first steps of developmental processes is demonstrated by mutations in the human MYCN gene being associated with birth defects. Mouse embryos defective for MYCN are unable to survive past embryonic stage E11.5 and exhibit hypoplasia in diverse organs and tissues: strongly reduced thickness of the encephalic walls, reduction of mature neurons in the ganglia of the trunk region, hearts underdeveloped often retaining the S-shape typical of 9-day-old embryos, marked underdevelopment in the lung airway epithelium, failure in the organisation of the mesonephros of the genitourinary system, absence of a bulging stomach structures. [11] [12] [13] [14] [15] [16] Moreover, in adult tissues, MYCN is expressed at early stages in developing B cells and at low levels in the brain, testis and heart. 17, 18 Nevertheless, it is widely accepted that MYCN expression undergoes a necessary decrease during differentiation processes; otherwise, high MYCN levels lead to a neoplastic phenotype. 19 The aim of this work was to study the role of the N-Myc protein in neuroblastoma differentiation processes, particularly during the early stages. Our hypothesis was that N-Myc might be necessary to activate neuroblastoma differentiation (mimicking embryonic development events) by regulating certain non-coding RNAs critical for differentiation.
Indeed, our data demonstrate that MYCN gene expression is required for neuroblastoma cells to activate the differentiation programme in the early stages. We found that N-Myc expression increased during the early differentiation phases, and its downregulation prevented differentiation in human neuroblastoma LAN-5 cells. Moreover, MYCN gene overexpression in the poorly differentiating neuroblastoma cell line SK-N-AS predisposed the cells to complete the differentiation process. These effects were accompanied by modulation of the apoptotic programme and were mediated by non-coding RNAs, which in turn regulated the expression of various apoptosis-related genes.
Results
Retinoic acid (RA) triggers differentiation in the human neuroblastoma LAN-5 cell line. First, we performed a comparative western blot analysis of the main proteins studied in the three cell models discussed in the paper (Supplementary Figure S1) . Figure 1a shows neurite outgrowth in LAN-5 cells cultured in a medium supplemented with 10 mM RA. Untreated cells continued expansion without changing morphology or shape; however, in RA-treated cells, neurite appeared after the first day of treatment and increased in number and length after 5 days. Moreover, neurite interconnections were stimulated by RA: the exposure caused the cells to form new networks. The expression of the differentiation marker neurofilament 200 (NF200) was induced by RA ( Figure 1b) .
Analysis of a group of typical molecular neuronal markers confirmed that RA treatment activated the differentiation programme in LAN-5 cells. Quantitative PCR (qRT-PCR) revealed increasing levels of GAP43, ChAT, MAPT, SLC18A, ENO2 and CDK5 ( Figure 1c) ; western blotting analysis of GAP43 and ChAT proteins confirmed the qRT-PCR data (Figure 1d) . Differentiation induction was offset by a reduction in the growth of RA-treated cells; the mean doubling time was approximately 27 h in control cells and 54 h in RA-treated ones (Supplementary Figure S2a) . RA prevented cell growth by arresting cells in the G0/G1 phase of the cell cycle (the percentage of cells in G0/G1 was 50.40% in control cells and 71.48% in RA-treated cells after 3 days of growth; Supplementary Figure S2b) . Moreover, a bromodeoxyuridine (BrdU) incorporation assay revealed reduced DNA synthesis after RA exposure. The percentage of cells incorporating BrdU was 53% for untreated control cells and 21% for RAtreated cells (Supplementary Figure S2c) . Consistent with the increase in the percentage of cells in the G0/G1 cell cycle phase, cyclin A was downregulated, and the kinase inhibitor p27 kip1 was upregulated (Supplementary Figure S2d) .
N-Myc expression increases during the early phases of RA-induced differentiation in cells of neural origin. LAN-5 cells showed an increase in N-Myc protein when exposed to RA. The maximal N-Myc expression was evident between the first and the third day of treatment (Figure 2a) . Afterwards, N-Myc expression levels started to decrease. Analysis of MYCN levels using qRT-PCR confirmed the results observed by western blot analysis, revealing a maximum of an approximately threefold enrichment of its mRNA during the early induction of differentiation ( Figure 2b ). We also examined the mRNA levels of a wellknown downregulated downstream target of N-Myc, N-Myc downstream-regulated gene 1 (NDRG1), 20 to verify the functional implications of MYCN upregulation. As expected, qRT-PCR analysis revealed that the modulation of the N-Myc target NDRG1 inversely paralleled MYCN modulation during differentiation ( Figure 2b ). The analysis of the sub-G1 fraction, indicative of apoptosis, during the RA-induced differentiation in LAN-5 cells revealed a peak in the sub-G1 region between the third and the fourth day of differentiation, when N-Myc expression was maximal (Figure 2c) .
The MYCN expression analysis conducted in mouse cortical embryonic neural progenitor cells induced to differentiate revealed that the MYCN levels in these cells tracked those observed in LAN-5 cells during differentiation (Figure 2d ). Evidently, MYCN expression increased during the early phases of differentiation and then decreased as expected. The observed increase in CDK5 expression was consistent with the activation of differentiation. Interestingly, a significant decrease in MYC expression was observed from the early phases of differentiation, further supporting the idea that the MYC and MYCN genes might have different roles in the differentiation programme.
N-Myc is necessary to activate the differentiation programme in LAN-5 neuroblastoma cells. To determine whether and to what extent MYCN has a determining role in early differentiation, we silenced its expression in MYCNamplified LAN-5 cells. We introduced an artificial miRNA to interfere with N-Myc expression. We evaluated N-Myc levels after downregulation, comparing Mock cells and MYCN-KD ones during RA treatment for 4 days (Figure 3a) . We obtained a decrease in protein levels of approximately 70%, maintained at similar level during RA-induced differentiation. The downregulation of the MYCN transcripts was approximately 40%, and the levels of the N-Myc downstream target NDRG1 were significantly upregulated (Figure 3b ).
Phase contrast microscopy revealed a strong reduction of neurite formation in MYCN-KD cells even after RA treatment. In contrast, Mock cells continued to present neurite extensions (Figure 3c ). In the same differentiation conditions in MYCN-KD cells, we did not observe any significant expression of the neurite marker NF200 (Figure 3d ).
We studied plasma membrane polarisation using flow cytometry and fluorescent dyes responsive to acute changes in the plasma membrane potential to determine functional effects of MYCN downregulation in LAN-5 cells. As expected, MYCN-KD cells were characterised by a reduced ability to polarise the plasma membrane compared with Mock cells. (Figure 4a ). In addition, the membrane hyperpolarisation usually observed in RA-differentiated cells was prevented when the MYCN gene was downregulated (Figure 4b ). We evaluated cell death in Mock and MYCN-KD cells by assessing the mitochondrial membrane potential. We found that the MYCN-silenced cells did not show any cell death after RA treatment, whereas the control Mock cells exposed to RA exhibited apoptosis (Figure 4c ), suggesting that MYCN might be necessary in the early phases of differentiation to induce apoptosis in cells not committed to differentiation.
The expression of the molecular neuronal markers previously analysed in the differentiating LAN-5 cells was also studied after MYCN silencing. We observed inhibited expression levels of all four markers analysed at day 3 after RA treatment (Figure 4d neuroblastoma cell line shows a very poor capacity to differentiate after stimulation with RA, and these cells have a single copy of the MYCN gene, thus showing no overexpression of this gene. 21 We overexpressed the MYCN gene in these cells (Figure 5a ) and studied differentiation activation after RA induction. The overexpression of the MYCN gene was also confirmed by the protein level (Figure 5b ). Figure 5c MYCN modulation modifies the expression of miRNAs involved in apoptosis preceding neuronal differentiation. The analysis of specific miRNAs selected by in silico analysis (miRWalk 22 ) and reported to be regulated by MYCN and at the same time involved in apoptosis and neuron development revealed changes in the expression of miR20a, miR-9 and miR-92a. We found that these miRNAs were upregulated in MYCN-silenced LAN-5 cells (Figure 6a ). In contrast, when MYCN was overexpressed in the SK-N-AS cells, the same miRNAs were downregulated ( Figure 6b ). In particular, the p53-family members have been reported to be regulated by these miRNAs. For this reason, we performed PCR array analysis of the p53 signalling pathway ( Figure 6c ). As expected, and consistent with the expression of miR-20a, miR-9 and miR-92a, the expression pattern observed in LAN-5 MYCN-KD cells was opposite to that in SK-N-AS MYCN þ cells with regard to genes known to be involved in cell death regulation. We found that pro-apoptotic CASP9 and BAI1 genes were upregulated in the MYCN overexpressing cells; whereas, the anti-apoptotic BCL2 gene was downregulated in the same MYCN condition. By contrast, CASP9 and BAI1 were downregulated and BCL2 was upregulated when MYCN was silenced. As well as, genes known to be involved in the activation of apoptotic programme such as E2F1, E2F3, GADD45A and FOXO3 were upregulated in MYCN-amplified and downregulated in MYCN-silenced cells, respectively. In addition, despite an analysis of validated miRNA targets using miRWalk database reported miR-20a, miR-9 and miR-92a target TP53, TP73 and TP63 mRNAs, the PCR array analysis did not reveal any modulation of TP53 mRNA levels (data not shown); whereas an upregulation of both TP73 (about sevenfold) and TP63 (more than twofold) was observed in MYCN-overexpressing cells (Figure 6c ).
Inhibition of miR-20a, miR-9 and miR-92a in the wild-type SK-N-AS cells restores apoptosis and their differentiation ability. We inhibited miR-20a, miR-9 and miR-92a in MYCN-non-amplified SK-N-AS cells avoiding any possible interference by MYCN (Figure 7a ).
The pro-apoptotic genes (CASP9, FOXO3, E2F1, E2F3, TP73) were upregulated by miRNAs inhibition after both 24 and 48 h. By contrast, TP63 was not upregulated suggesting no correlation between miR-20a, miR-9 and miR-92a and TP63 expression (Figure 7b ). Interestingly, RA was able to activate apoptosis after miRNAs inhibition in SK-N-AS cells (Figure 7c ). Whereas control cells did not present any significant induction of apoptosis by RA treatment (Figure 7c ).
Differentiation markers were upregulated after the inhibition of the three miRNAs at both 24 and 48 h in the presence of RA induction ( Figure 7d ). As expected, MYC was downregulated in differentiating cells.
In Figure 8a , we summarised our data presenting a hypothetical mechanism by which MYCN could trigger the 
Discussion
Several studies of MYC-and MYCN-knockout mice have revealed that embryos of these mice could not survive until gestation, 11, 14, 16, 23, 24 suggesting that the MYC family genes are required for normal development at the beginning of organogenesis. In particular, Knoepfler et al. 24 showed that N-Myc has an important role in complete nervous system development. In fact, loss of N-Myc function during embryogenesis interrupts the ability of neural progenitors to expand, differentiate and populate the brain, causing neurological dysfunction after birth. Unlike c-Myc, which is expressed in all proliferating cells, N-Myc expression is more restricted. Appropriate spatial and temporal expression of N-Myc are important for normal embryonic development. 25 Accordingly, we show that upregulation of the MYCN gene is restricted to the early stages of differentiation induction in mouse cortical embryonic neural progenitor cells. In addition, as expected, MYC gene expression decreased during differentiation progress. These data suggest that the MYCN gene might have a critical role in the activation of neuronal differentiation. Nevertheless, as also reported by others, 19, 26, 27 differentiation completion was later associated with a decrease in MYCN expression. It is likely that the N-Myc protein, as a transcription factor, is necessary at the onset of neuronal differentiation to establish the expression of a set of genes essential for subsequent phases.
To examine the role of N-Myc in the neuronal differentiation programme, we used the human neuroblastoma cell line LAN-5, which show MYCN gene amplification. 28 The LAN-5 cell line, similar to many others neuroblastoma cell lines, maintains the ability to differentiate in vitro in the presence of specific stimuli, such as RA. 28, 29 In fact, our results confirm that LAN-5 cells treated with RA form neurites; express the neuronal marker NF200, an intermediate filament that provides structural stability to the axon; and show the induction of a series of neuronal molecular markers. In agreement with previous papers, 27, 30 GAP43 and MAPT were upregulated in differentiated LAN-5 cells; in addition, ChAT and SLC18A appeared to have increased expression after differentiation induction in the LAN-5 cell line, which is normally committed to cholinergic differentiation. 2 As expected, successful development is associated with cell proliferation inhibition, demonstrated by cell cycle analysis performed using various approaches. Figure 8 Model of the hypothetical role of MYCN during the early phases of neuroblastoma differentiation. (a) MYCN overexpression inhibits miR-9, miR-20a and miR92a. We hypothesise that this inhibition allows targets of these miRNAs (E2F genes, TP73 and FOXO3) to be upregulated and in turn to activate apoptosis in those cells not committed to differentiate but still proliferating. In contrast, MYCN downregulation allows the overexpression of miR-9, miR-20a and miR-92a, preventing the upregulation of apoptosis-related genes, thus inhibiting apoptosis and subsequent differentiation. In addition to what has been observed previously, 19, 26, 27 we found peak MYCN expression during the first days of RA-induced differentiation in LAN-5 cells. We demonstrated the functionality of the increased N-Myc protein through expression analysis of the N-Myc target NDRG1, which decreased as expected. 20 Furthermore, differentiation was inhibited by MYCN silencing in the same model; this was indicated by the failure of neurite outgrowth, the decrease in known neuronal molecular markers and the loss of NF200 expression during differentiation. In addition, the plasma membrane of the MYCN-KD LAN-5 cells depolarised and was no longer able to hyperpolarise in response to differentiation stimuli. Plasma membrane polarisation is a parameter known to be essential for differentiated neuronal cells. 31 In addition, when MYCN is overexpressed in cells with a poor differentiation capacity, developmental processes are restored. This pattern was observed in SK-N-AS MYCN þ cells, in which neurite outgrowth occurred, and the expression of NF200 and known molecular neuronal markers increased after RA treatment.
These data, taken together, demonstrate that N-Myc protein expression is required to activate the differentiation processes in neuroblastoma cells.
To explore the mechanisms by which N-Myc could trigger differentiation in neuroblastoma cells, we studied the expression levels of miR20a, miR-9 and miR-92a, which have been reported to be involved in differentiation processes and to be modulated by MYCN. 32, 33 Through the up-or downregulation of the MYCN gene, we observed that all the three miRNAs were decreased or increased, respectively. Consistently, the inverse relationship between these miRNAs and the cell differentiation status suggests that their downregulation is needed for differentiation triggering. In fact, according to the miRWalk database, two of the validated targets of these miRNAs are the RA receptor genes RARA and RARG.
34,35
The upregulation of miR-92a following MYCN silencing and its downregulation by RA treatment are in agreement with Chen and Stallings, 36 who showed that the expression of different miRNAs correlates with neuroblastoma prognosis, differentiation and apoptosis, also in response to RA. Moreover, consistently with Haug et al., 37 who found that miR-92 inhibits the secretion of the tumour suppressor gene DKK3 in neuroblastoma, our data demonstrated the downregulation of miR-92a in cells with a restored ability to differentiate, characteristic of a less malignant phenotype. Our findings are also supported by the data of Jee et al., 38 which showed that inhibition of miR-20a expression induces definitive motor neuron survival and neurogenesis. Consistent with results of Yoo et al., 39 showing that miR-9 is repressed in neural proliferating progenitors and is sequentially re-expressed in post-mitotic neurons, is the modulation of miR-9 we observed in LAN-5 cells during the RA kinetics (see Figure 8b , middle panel).
In agreement with O' Donnell et al. 40 and Coller et al., 41 we demonstrated that miR-20a negatively regulates the E2F factor genes. The transactivating p73 isoforms are transcriptionally induced by E2F and contribute to E2F-mediated apoptosis. [42] [43] [44] Consistent with these data, upregulation of TP73 and E2F was observed in MYCN þ cells and after miRNAs inhibition in SK-N-AS cells. Moreover, as expected, when MYCN was downregulated, and miR-20a and miR-92a were consequently upregulated, E2F and TP73 were inhibited. The role of p73 in the induction of neuronal differentiation has been previously highlighted by De Laurenzi et al., 45 who showed an increase in p73 protein levels after RA stimuli in murine neuroblastoma cells. In apparently disagreement with our data, they also showed reduced N-Myc protein levels after RA treatment as a marker of neuronal differentiation. 45 Indeed, they analysed N-Myc expression after 6 days of RA treatment, whereas, although our data demonstrated a peak in N-Myc protein expression between the second and the third day of differentiation induction, we also observed a subsequent decrease at day 5 of differentiation. It is likely that N-Myc, by downregulating miR-20a and miR-92a, produces the increase in E2Fs gene expression, which in turn induces TP73 transcription. Interestingly, RA treatment in LAN-5 cells confirmed the presence of a hierarchy between E2Fs and TP73, which are overexpressed at day 1 and day 4 of RA treatment, respectively.
In addition, we found FOXO3 upregulated in differentiating MYCN þ cells and in RA-treated LAN-5 cells. The human FOXOs transcription factor family regulates the expression of genes associated with multiple biological processes such as cell cycle arrest and apoptosis. 46 As demonstrated by Senyuk et al., 47 miR-9 is able to bind directly to the 3 0 UTR of FOXO3. In fact, when we silenced the MYCN gene in LAN-5 cells, an increase in miR-9 and a consequent decrease in FOXO3 mRNA levels were obtained. These data are further demonstrated by the increase in FOXO3 expression achieved after inhibiting miRNAs in SK-N-AS cells.
We reasoned that the miR-20a, miR-9 and miR-92a inhibition in MYCN þ , as well as, in RA-treated LAN-5 cells and the subsequent pro-apoptotic genes increase could be a necessary step before differentiation programme. In fact, the inhibition of miR-20a, miR-9 and miR-92a in the MYCN-nonamplified SK-N-AS cells restored the ability of these cells to respond to RA treatment, as demonstrated by Annexin V assay and differentiation-related gene expression analysis.
Even though the overexpression of MYCN in SK-N-AS cells resulted in a downregulation of miR-92a and an upregulation of TP63, we did not observe an increase of TP63 after inhibiting miR-92a. It is likely that other pathways downstream MYCN are involved in TP63 regulation. More studies are needed to establish if TP63 is directly or indirectly activated by N-Myc.
Therefore, we hypothesise that MYCN is necessary during the activation of neuroblastoma differentiation to induce apoptosis in cells that are not committed to differentiation but are still proliferating. Programmed cell death is a necessary physiological process and involves a large number of developing neurons during nervous system development 48 and in adult neurons. 49 Materials and Methods Cell line maintenance, differentiation and treatments. LAN-5 and SK-N-AS human neuroblastoma cell lines (both gifts of Dr. Doriana Fruci) were grown in RPMI-1640 medium (Gibco, Paisley, UK) supplemented with 10% FBS (Hyclone, South Logan, UT, USA), 2 mM L-glutamine, 10 U/l penicillin and 10 U/l streptomycin in a humidified incubator containing 5% CO 2 at 37 1C. LAN-5 cells contain amplified MYCN, 28 whereas SK-N-AS cells are MYCN single copy. 21 Embryonic neural precursor cells (gift of Professor Stefano Biagioni and Dr. Emanuele Cacci) were cultured and differentiated as previously described. 50 For differentiation experiments, LAN-5 cells were seeded at a density of 5 Â 10 3 cells/cm 2 . The following day, the cells were induced to differentiate with 10 mM retinoic acid (ATRA, designated RA throughout the paper; Sigma-Aldrich, St. Louis, MO, USA) in 'differentiation medium' composed of 50% fresh and 50% conditioned culture medium. The cells were fed after 3 days with differentiation medium containing fresh RA. RA was dissolved in dimethyl sulphoxide (Sigma-Aldrich) and stored as a stock solution at À 80 1C. SK-N-AS cells were seeded at a density of 3.5 Â 10 3 cells/cm 2 . The following day, the cells were induced to differentiate by adding 1 mM RA in a 'differentiation medium' composed of RPMI þ 1% FBS. Because of the light sensitivity of RA, all incubations were performed under subdued lighting. The dimethyl sulphoxide concentration in each experiment was always r0.01%, which was not toxic and did not induce differentiation.
A comparative western blot analysis has been conducted in the three cell lines employed in this work to evidence basal expression level of the main mentioned proteins (Supplementary Figure S1) .
Neurite quantification. After RA treatment, the cells were viewed with a Leica DM IRB inverted phase contrast microscope at Â 200 (Leica, Wetzlar, Germany). The cells were scored as differentiated if the length of the neurite extensions was at least twice the diameter of the cell body. The neurites were evaluated based on the percentage of cells bearing neurites as determined from the cell culture images, which facilitated tracing the individual neurites and eventual branch points. A total of 4300 cells was examined in five randomly chosen fields in each treated and untreated sample. The projection images were semiautomatically traced with NIH ImageJ using the NeuronJ plugin. The total dendritic length of each individual neuron was analysed.
Western blot analyses. Cultured cells were washed twice with 1 Â PBS and then incubated for 1 min in urea buffer (8 M urea, 100 mM NaH 2 PO 4 and 10 mM Tris pH 8), scraped, harvested and briefly sonicated. The proteins were subjected to SDS-polyacrylamide gel electrophoresis. The resolved proteins were blotted overnight onto nitrocellulose membranes, which then were blocked in 1 Â PBS containing 5% non-fat milk for at least 1 h. The blots were incubated with the following primary anti-human antibodies: rabbit polyclonal anti-N-Myc (C-19; Santa Cruz Biotechnology, Dallas, TX, USA); mouse monoclonal anti-GAP43 (GAP-7B10; Sigma-Aldrich); rabbit polyclonal anti-CDK5 (Cell Signaling Technology, Danvers, MA, USA); mouse monoclonal anti-cyclin A (C-19; Santa Cruz Biotechnology); rabbit polyclonal anti-p27 kip1 (C-19; Santa Cruz Biotechnology); goat polyclonal anti-ChAT (Millipore, Billerica, MA, USA); mouse monoclonal anti-GAPDH (6C5; Millipore) and mouse monoclonal anti-HSP 72/73 (Ab1-W27; Oncogene Science Inc., Cambridge, MA, USA). The membranes were then incubated for 45 min with the appropriate secondary antibody: donkey anti-rabbit IRdye800 (LI-COR Biosciences, Lincoln, NE, USA); donkey anti-mouse IRdye800 (LI-COR) or donkey anti-goat IRdye800 (LI-COR). The membranes were then analysed with a Licor Odyssey Infrared Image System in the 800 nm channel. Blot scan resolution was 150 d.p.i.
Immunofluorescence. The cells were seeded on coverglass supports in complete medium and treated with RA for the indicated times. The cells were fixed with 4% (w/v) paraformaldehyde and permeabilised in PBS containing 0.1% Triton-X 100. NF200 was detected using an anti-NF200 monoclonal antibody (N52; Sigma-Aldrich). Alexa Fluor 594 goat anti-mouse antibody (Molecular Probes, Paisley, UK) was used as a secondary antibody. The antibodies were diluted in PBS. Cell nuclei were stained with 1 mg/ml DAPI or Hoechst 33342 in PBS for 5 min. Finally, the cells were washed in PBS and briefly rinsed in ddH 2 O, and the coverglass slips were mounted in ProLong Gold anti-Fade Reagent (Molecular Probes). Images were acquired with an Olympus BX51 fluorescence microscope and analysed with I.A.S. software (Delta Sistemi, Legnano (VR), Italy). The brightness and contrast of the acquired images were adjusted, and the figures were generated using Adobe Photoshop 7.0.
Total RNA preparation. The cells were seeded in complete medium and harvested after the different treatments; total RNA was isolated using a Total RNA purification kit (Norgen Biotek, Thorold, ON, Canada). RNA quantity was determined by absorbance at 260 nm using a NanoDrop UV-VIS spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). The quality and integrity of each sample were confirmed using a BioAnalyzer 2100 (RNA 6000 Nanokit; Agilent, Santa Clara, CA, USA); samples with an RNA Integrity Number index lower than 8.0 were discarded. Cell cycle analysis. Cell cycle analysis was performed by pulse-chase BrdU (Sigma-Aldrich) incorporation and propidium iodide (PI) DNA staining. For BrdU incorporation, a pulse of 10 mM BrdU was added to the cell culture during the last 30 min before harvesting. Cells were fixed in ethanol 70% at þ 4 1C for at least 1 h, and then processed as previously described. Primary anti-BrdU (BD Biosciences Italia, Buccinasco (MI), Italy) and secondary FITC-conjugated F(ab 0 )2 rabbit anti-mouse IgG (DAKO, Glostrup, Denmark) antibodies were used to detect the BrdU. Finally, after washing in PBS/BSA 0.5%, cells were stained with a solution containing 5 mg/ml PI and 75 KU/ml RNase overnight in dark. For PI staining, cells fixed in ethanol 70% for at least 1 h were stained in a solution containing 50 mg/ml PI and 75 KU/ml RNase for at least 30 min in the dark. In each case, 20 000 events per sample were acquired by using a FACScan cytofluorimeter and the CellQuest BD software. BrdU-positive cells represent the fraction of the cell population synthesising DNA. The percentages of the cells in the different cell cycle compartments were estimated on linear PI histograms by using the MODFIT software (Verity, Topsham, ME, USA).
Apoptosis detection. Apoptosis was detected in the specific conditions by using Annexin V assay, mitochondrial membrane potential measurement and estimation of sub-G1 fraction. Description of these methods have been detailed in previous papers. 51, 52 MYCN silencing. Proliferating LAN-5 cells were transfected with a plasmid (pcDNA6.2-GW/EmGFP-miR-MYCN) targeting MYCN mRNA and a non-silencing plasmid (pcDNA6.2-GW/EmGFP-miR-Neg) with no homology to mammalian genes, using Lipofectamine2000 (Life Technologies) according to the manufacturer's instructions. We used 2 mg of plasmid. After transfection, the cells were selected with blasticidin for 2 weeks before performing experiments.
MYCN overexpression. Proliferating SK-N-AS cells were transfected with a plasmid carrying the MYCN construct driven by the CMV promoter or a BlueScript control vector using Lipofectamine2000 (Life Technologies) according to the manufacturer's instructions. We used 2 mg of DNA per sample. At 24 h after the transfection, the cells were induced to differentiate by exposure to RA for 3 days using a specific differentiation protocol (see above).
Plasma membrane potential analysis. LAN-5 plasma membrane potential was measured by flow cytometry using the voltage-sensitive fluorescent dye DiOC 5 (Molecular probes). The cells were harvested and washed once in PBS þ 0.1 M glucose, and 1 Â 10 6 cells were incubated in a solution containing 50 nM DiOC 5 at 37 1C for 15 min. The samples were then washed once in PBS þ 0.1 M glucose and immediately assessed by flow cytometry. As a depolarised control, we used a sample post-incubated with the oxidative phosphorylation inhibitor 4-trifluoromethoxyphenylhydrazone; as a hyperpolarised control, we used a sample incubated with the potassium-specific transporter valinomycin. PI at a final concentration of 10 mg/ml was added to each sample immediately before the measurements to exclude non-viable cells from the analysis. A total of 10 000 events was acquired for each sample using a FACScan cytofluorimeter.
Statistical analysis. Statistical significance of differences between groups was tested by paired Student's t-test or, if there were more than two groups, by one-way ANOVA.
